Definition Rare, lethal chromosomal abnormality. An entire extra haploid set of chromosomes results in 69 chromosomes instead of the usual 46.
Epidemiology Of human conceptions, 1% to 2% are triploid, but most end in spontaneous abortion. Accounts for 20% of chromosomally abnormal spontaneous abortions. Very rare at birth, occurring in 1 in 10,000 live births.
Embryology A complete extra set of chromosomes results in 69 XXX (digynic) or XXY (diandric). Sixty percent result from fertilization with two sperm; 40% result from fertilization of a diploid egg. However, more recent prospective information, at the time of first-trimester screening, suggests that digynic triploidy may be more common than diandric. Central nervous system malformations include hydrocephalus, holoprosencephaly, and neural tube defects. Hypertelorism, cleft lip/cleft palate, syndactyly of the third and fourth fingers, and congenital heart defects are typical features.
Inheritance Patterns Sporadic
Teratogens None
Screening Serum levels of human chorionic gonadotropin and inhibin A may be extremely high in triploidy with dispermy as the cause. Very low levels of α-fetoprotein, estriol, inhibin A, and human chorionic gonadotropin (hCG) are seen in pregnancies in which fertilization of a diploid egg occurs. In the first trimester, screening, using nuchal translucency and serum markers will detect approximately 85% of fetuses with triploidy. Diandric triploids have an increased nuchal translucency, elevated hCG, and normal, or low, pregnancy-associated plasma protein A (PAPP-A). Digynic triploidy has a normal nuchal translucency, very low hCG, and very low PAPP-A. Diandric triploidy will generally look like an increased risk for trisomy 21, and digynic will generally look like a high risk for trisomy 18.
Prognosis Lethal antenatally or in the newborn period. Rare mosaic cases survive with moderate-to-severe mental retardation.
Findings: Sonographic findings vary with the source of the extra chromosome.
First-trimester thickened nuchal translucency
Intrauterine growth restriction
Asymmetric growth restriction with large fetal head is associated with digynic triploidy
There is early-onset symmetrical growth restriction.
Some fetuses with diandric triploidy have grown normally.
Ventriculomegaly
Holoprosencephaly
Micrognathia
Low-set ears
Single umbilical artery
Syndactyly of third and fourth fingers
Clubfeet
Oligohydramnios
Enlarged placenta with multiple cystic spaces; similar to a partial mole (diandric, XXY)
Small placenta (digynic, XXX)
Bilateral theca lutein cysts
Neural tube defects
Dandy-Walker malformation
Agenesis of the corpus callosum
Microphthalmia
Hypertelorism
Cystic hygroma
Coarctation of aorta
Hypoplastic left ventricle
Omphalocele
Pyelocaliectasis
Ambiguous genitalia
Nonimmune hydrops
Pleural effusion
Pericardial effusion
Ascites
Anasarca
Investigations and Consultations Traditional karyotyping with, or without, fluorescent in situ hybridization (FISH) analysis via amniocentesis or chorionic villi sampling (CVS) establishes the diagnosis. Once a cytogenetic diagnosis has been established, no further investigations or consultations are necessary. For patients in whom the diagnosis is made beyond the point of legal pregnancy termination or in those who decide to continue the pregnancy, a neonatologist should consult with the family about appropriate perinatal and neonatal management. The family should be offered supportive psychological care throughout the pregnancy.
Monitoring If pregnancy termination is not an option, monitor for preeclampsia or hyperthyroidism. Either of these complications is an indication for treatment, including immediate delivery without regard to gestational age.
Pregnancy Course Molar changes in the placenta predispose to hyperemesis gravidarum, early preeclampsia, theca lutein cysts, and, on occasion, hyperthyroidism. Prenatal care should be modified such that only interventions for maternal health, rather than fetal health, are offered. Intrauterine growth restriction is common, and aggressive management with fetal monitoring is inappropriate.
Pregnancy Termination Issues Use of suction dilatation and evacuation, or any other method of pregnancy termination, is appropriate once a cytogenetic diagnosis has been established.
Delivery Fetal monitoring and cesarean section are both contraindicated for the pregnancy complicated by a triploidy.
Resuscitation Contraindicated if the diagnosis is definite because of the established lethal prognosis.
Transport Indicated only if diagnostic confirmation, counseling, and long-term care planning are not available locally.
Testing and Confirmation A peripheral blood chromosome study can confirm the chromosome abnormality.
Nursery Management Provision of basic supportive care—warmth, hygiene, nourishment, and comfort only— until prognosis for protracted survival is defined and long- term care decisions can be addressed with the family.
Definition Because of its higher intrauterine mortality, trisomy 13 is the least common of the major autosomal trisomies. Fetuses with trisomy 13 tend to have more craniofacial (median cleft, micro- or anophthalmia) and brain (holoprosencephaly) abnormalities. While trisomy 13 is frequently referred to as lethal, this is not always the case. The median survival is 7 days, and 90% of trisomy 13 newborns die by 1 year of age.
Epidemiology One in 5000 to 10,000 births
Embryology The phenotype is due to full trisomy 13. Increased maternal age has been documented in this disorder. Rare mosaic partial trisomy 13 syndromes (with varying phenotypes) and translocation patients have been reported. Microcephaly, holoprosencephaly, microphthalmia, polydactyly, and facial clefts are found in more than 50% of patients. Eighty percent of patients have congenital heart defects, with atrial septal defects (ASDs) and ventricular septal defects (VSDs) the most common. However, many patients have complex heart lesions. Other distinctive abnormalities include polycystic kidneys (30% of patients) and omphalocele (<50% of patients).
Inheritance Patterns Most cases are sporadic, with approximately a 1-in-100 risk of recurrence in future pregnancies. Rare familial translocations have a higher recurrence risk, depending on the specific translocation.
Teratogens None
Screening Second-trimester maternal serum biochemical marker screening is not helpful in detecting trisomy 13 fetuses. Some cases are diagnosed by first-trimester screening because of increased nuchal translucency and fetal malformations. Noninvasive prenatal testing (NIPT) will detect 90% to 95% of cases.
Prognosis This condition is lethal or has a very poor prognosis in all cases. Live births occur in 40% to 60%, but 90% die in the first year. All survivors with full trisomy 13 have profound mental retardation. In infancy, severe failure to thrive, feeding difficulties, seizures, apneic attacks, and visual and hearing deficits occur in the majority of infants, secondary to the orofacial and central nervous system defects.
Findings: The number and severity of congenital anomalies associated with trisomy 13 are highly variable.
First-trimester thickened nuchal translucency
Holoprosencephaly
The presence of a cavum septum pellucidum excludes a significant forebrain abnormality.
Microcephaly
Central cleft lip and palate
Enlarged cisterna magna
Hypotelorism
Low-set ears
Polydactyly
Clubfeet
Congenital heart defect
Ventricular septal defect
Atrial septal defect
Hypoplastic left ventricle
Aortic stenosis
Pulmonary stenosis
First-trimester megacystis
Agenesis of the corpus callosum
Cerebellar hypoplasia
Basal ganglia calcifications
Single orbit with 2 globes, cyclops
Microphthalmia
Single nostril
Proboscis
Rocker-bottom feet
Clubhands
Overlapping fingers
Echogenic enlarged kidneys containing small cysts
Omphalocele
Neural tube defect
Investigations and Consultations Traditional karyotyping with, or without, FISH analysis via amniocentesis or CVS establishes the diagnosis. A positive result from maternal blood of cell-free circulating fetal DNA is considered a screening test and is not sufficient to establish the diagnosis. Once a cytogenetic diagnosis has been established, no further investigations or consultations are necessary. For patients in whom the diagnosis is made beyond the point of legal pregnancy termination or in those who decide to continue the pregnancy, a neonatologist should consult with the family about appropriate perinatal and neonatal management. The family should be offered supportive psychological care throughout the pregnancy.
Monitoring Only routine prenatal care should be performed. Monitoring for preeclampsia is appropriate, as it is more common in pregnancies complicated by trisomy 13. This complication is an indication for treatment, including immediate delivery, without regard to gestational age.
Pregnancy Course Prenatal care should be modified such that only interventions for maternal health, rather than fetal health, are offered. Intrauterine growth restriction is common, and aggressive management with fetal monitoring is inappropriate.
Pregnancy Termination Use of suction dilatation and evacuation, or any other method of pregnancy termination, is appropriate once a cytogenetic diagnosis has been established.
Delivery Electronic fetal monitoring and cesarean section should be avoided unless requested by the family after a thorough discussion of the prognosis for infants with trisomy 13.
Resuscitation A decision about whether to give life support should be made prior to delivery, once the diagnosis is established. If the diagnosis is unknown prior to birth, providing life support is appropriate until a diagnosis can be established.
Transport Indicated only if diagnostic confirmation, counseling, and long-term care planning are not available locally.
Testing and Confirmation Obtain peripheral blood, or cord blood, for chromosome analysis to confirm the diagnosis.
Nursery Management Full life support is appropriate until the diagnosis is confirmed and the family has time for weighing options for duration and intensity of support. Care requirements will be contingent on associated organ involvement and the long-term goals of the family.
FIGURE 1.2B
Normal cavum septum pellucidum (arrow).